Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55. https://doi.org/10.1016/S0140-6736(21)02724-0.

Article  Google Scholar 

Saharman YR, Karuniawati A, Severin JA, Verbrugh HA. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review. Antimicrob Resist Infect Control. 2021;10:22. https://doi.org/10.1186/s13756-020-00871-x.

Article  PubMed  PubMed Central  Google Scholar 

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022–2020 data. Copenhagen: WHO Regional Office for Europe; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf. Accessed 27 Jan 2025.

Pham HN, Than TDN, Nguyen HA, Vu DH, Phung TH, Nguyen TK. Antibiotic resistance, biofilm formation, and persistent phenotype of Klebsiella pneumoniae in a Vietnamese tertiary hospital: a focus on amikacin. Microb Drug Resist. 2024;30:203–9. https://doi.org/10.1089/mdr.2023.0267.

Article  CAS  PubMed  Google Scholar 

Vu TVD, Choisy M, Do TTN, Nguyen VMH, Campbell JI, Le TH, et al. Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017. Antimicrob Resist Infect Control. 2021;10:78. https://doi.org/10.1186/s13756-021-00937-4.

Article  PubMed  PubMed Central  Google Scholar 

Tran TN, Vu DH, Nguyen HA, Abrams S, Bruyndonckx R, Nguyen TT, et al. Predicting mortality in intensive care unit patients infected with Klebsiella pneumoniae: a retrospective cohort study. J Infect Chemother. 2022;28:10–8. https://doi.org/10.1016/j.jiac.2021.09.001.

Article  PubMed  Google Scholar 

Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther. 2017;15:519–26. https://doi.org/10.1080/14787210.2017.1316193.

Article  CAS  PubMed  Google Scholar 

Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update. 2011;14:107–17. https://doi.org/10.1016/j.drup.2011.02.005.

Article  CAS  Google Scholar 

Ruiz J, Ramirez P, Company MJ, Gordon M, Villarreal E, Concha P, et al. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients. J Glob Antimicrob Resist. 2018;12:90–5. https://doi.org/10.1016/j.jgar.2017.09.019.

Article  PubMed  Google Scholar 

Agence francaise de securite sanitaire des produits de sante. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect. 2012;42:301–8. https://doi.org/10.1016/j.medmal.2011.07.007.

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints and dosing of antibiotics. version 11.0. Available from: https://eucast.org/clinical_breakpoints/. Accessed 31 Dec 2021.

Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–53. https://doi.org/10.1007/s00134-020-06050-1.

Article  PubMed  PubMed Central  Google Scholar 

Frost KJ, Hamilton RA, Hughes S, Jamieson C, Rafferty P, Troise O, et al. Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations. Eur J Hosp Pharm. 2023;35:496–504. https://doi.org/10.1136/ejhpharm-2022-003421.

Article  Google Scholar 

White BP, Lomaestro B, Pai MP. Optimizing the initial amikacin dosage in adults. Antimicrob Agents Chemother. 2015;59:7094–6. https://doi.org/10.1128/AAC.01032-15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–34. https://doi.org/10.2165/00003088-200544100-00002.

Article  CAS  PubMed  Google Scholar 

Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003–12. https://doi.org/10.1128/AAC.43.5.1003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71:208–12. https://doi.org/10.1093/jac/dkv291.

Article  CAS  PubMed  Google Scholar 

Sadeghi K, Hamishehkar H, Najmeddin F, Ahmadi A, Hazrati E, Honarmand H, et al. High-dose amikacin for achieving serum target levels in critically ill elderly patients. Infect Drug Resist. 2018;11:223–8. https://doi.org/10.2147/IDR.S150839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Queensland Health. Aminoglycoside dosing in adults. Brisbane: State of Queensland; 2018. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0019/713323/aminoglycoside-guidelines.pdf. Accessed 27 Jan 2025.

Bauer LA. The aminoglycoside antibiotics. Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Education / Medical; 2014.

Saez Fernandez EM, Perez-Blanco JS, Lanao JM, Calvo MV, Martin-Suarez A. Evaluation of renal function equations to predict amikacin clearance. Expert Rev Clin Pharmacol. 2019;12:805–13. https://doi.org/10.1080/17512433.2019.1637253.

Article  CAS  PubMed  Google Scholar 

Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84. https://doi.org/10.1159/000339789.

Article  PubMed  Google Scholar 

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100, USA; 2024.

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance document EUCAST breakpoints in brackets. 2021. Available from: https://www.eucast.org/bacteria/guidance-documents/. Accessed 2 Dec 2021.

Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94. https://doi.org/10.1016/j.cmpb.2003.11.003.

Article  PubMed  Google Scholar 

Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometr Syst Pharmacol. 2019;8:538–56. https://doi.org/10.1002/psp4.12422.

Article  CAS  Google Scholar 

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometr Syst Pharmacol. 2013;2:e38. https://doi.org/10.1038/psp.2013.14.

Article  CAS  Google Scholar 

Lindbom L, Pihlgren P, Jonsson EN. PsN-toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57. https://doi.org/10.1016/j.cmpb.2005.04.005.

Article  PubMed  Google Scholar 

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. https://doi.org/10.1159/000180580.

Article  CAS  PubMed  Google Scholar 

Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–9. https://doi.org/10.1093/infdis/155.1.93.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA/CHMP/594085/2015). 2016. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf. Accessed 30 Sep 2021.

Joint Formulary Committee. British national formulary. Available from: https://bnf.nice.org.uk/treatment-summary/aminoglycosides.html. Accessed 9 Nov 2021.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–111. https://doi.org/10.1093/cid/ciw353.

Article  PubMed  PubMed Central  Google Scholar 

Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521–47. https://doi.org/10.1016/j.cmi.2021.11.025.

Article  CAS  PubMed  Google Scholar 

European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance document on implementation and use of the revised aminoglycoside breakpoints. 2020. Available from: https://www.eucast.org/bacteria/guidance-documents/. Accessed 15 Sep 2023.

Carrie C, Delzor F, Roure S, Dubuisson V, Petit L, Molimard M, et al. Population pharmacokinetic study of the suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy. Antimicrob Agents Chemother. 2020;64:e02098–19. https://doi.org/10.1128/AAC.02098-19.

Article